Corrigendum to ‘Autologous hematopoietic stem cell transplantation of patients with aggressive relapsing-remitting multiple sclerosis: Danish nation-wide experience’ [Multiple Sclerosis and Related Disorders Vol 76 (2023) 104829]

•In the whole cohort, no evidence of disease was 69% two years post-AHSCT.•Data suggests that CY is as effective as BEAM with less adverse events.•We had no treatment related mortality and only few severe adverse events.•AHSCT of patients with aggressive RRMS was an effective and safe treatment in Denmark.